Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 5 Beauty Startup Investors in Switzerland in January 2025

Last updated: Jan 2025 A list of 5 angel investors and VC (Venture Capital) funds that invest in Beauty startups based in Switzerland. We rank investors based on the number of investments they made in Beauty companies from Switzerland. We update this investor list every month.

Top 5 Beauty Startup Investors in Switzerland in January 2025

Investor	Beauty Switzerland investments
Ertan Wittwer	2
Yellowstone Holding	1
UZH Life Sciences Fund	1
Zürcher Kantonal Bank	1
Giammaria Giuliani	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Ertan Wittwer is the Founder and Board Member bestsmile. He attended BBZ Uzwil.

Show more

Investment focus

Health Care, Water, Beauty
Seed, Angel, Pre-Seed
Switzerland, United States

Portfolio highlights

Akina — Akina is developing the future of gamified digital healthcare to benefit individuals with chronic diseases around the world.
Noriware — Noriware wants to revolutionize the packaging industry by offering a truly sustainable, home-compostable alternative to traditional plastic, through unlocking the potential of seaweed. In doing so, we want to be the leader in transparency to motivate the industry to become more sustainable.
Alpine White — Alpine White is a healthcare startup that manufactures personal care products and treatments for its consumers. They exist to keep teeth healthy and white through great products and services that empower people to feel confident and feel good.

Yellowstone Holding promoting new innovative products or technologies from Switzerland to the Asia market via our strong connections.

Show more

Investment focus

Beauty, Cosmetics, Navigation
Series A, Series B
Switzerland

Portfolio highlights

CUTISS — CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns.
Medyria — Medyria is a Swiss medtech startup that engineers technologies for cardiovascular catheter navigation and sensing. They develop a unique guiding and sensing medical device based on proprietary Blood Flow Velocity Sensor technology. The TrackCath System is designed to be cost-effective and safe during EVAR procedures.Medyria's goal is todevelop devices that enable safer and more effective endovascular procedures. It was founded in 2014 and is based in Winterthur, Zurich, Switzerland.

The UZH Life Sciences Fund involves two equal partners: the UZH Foundation and the Novartis Venture Fund. It seeks donations from private individuals, foundations and companies for the strategic priorities of the University of Zurich.

Show more

Investment focus

Health Care, Biotechnology, Medical Device
Funding Round, Seed, Convertible Note
Switzerland

Portfolio highlights

Occlufit — Occlufit is an occluder device that conforms to complex geometries and provides immediate sealing of cardiovascular defects.
Navignostics — Navignostics combines highly multiplex tumor imaging with advanced data analytics for personalized cancer treatments.
ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.

Zürcher Kantonalbank - as an independent, incorporated public-law institution - is wholly owned by the canton of Zurich.

Show more

Investment focus

Health Care, Medical Device, Biotechnology
Seed, Series A, Funding Round
Switzerland, Japan, Spain

Portfolio highlights

Somagenetix — Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses. Somagenetix's mission is to use genetically modified phagocytes to treat patients suffering from immunodeficiency, neurodegeneration, and cancer with brain metastases.
Retinai — RetinAI optimises and simplifies clinics, research and pharmaceutical workflows to improve healthcare. To achieve this goal, the company builds tools to collect, analyze and organize health data, empowering healthcare professionals and patients with automatic image and data analysis supported by advanced machine learning. RetinAI has proprietarytechnology that provides unforeseen image quality enhancement, as well as automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies and device manufacturers at similar level of performance as a human would produce.
Lymphatica Medtech — Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle.

Giammaria Giuliani

Show more

Investment focus

Beauty, Cosmetics
Series A, Series B
Switzerland

Portfolio highlights

CUTISS — CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns.

Investors by industry

Artificial intelligence

Venture Capital

Food and Beverage

Financial Services

Enterprise Software

Mobile Advertising

Wine And Spirits

Renewable Energy

Agriculture (agtech)

Media (entertainment)

Investors by country

Russian Federation

Dominican Republic

United Arab Emirates

Marshall Islands

Investors in Switzerland by industry

Venture Capital

Food and Beverage

Enterprise Software

Mobile Advertising

Artificial intelligence

Renewable Energy

Financial Services

Agriculture (agtech)

Media (entertainment)